【𝗚𝗹𝗼𝗯𝗮𝗹 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲: 𝗪𝗼𝗿𝗹𝗱 𝗛𝗲𝗮𝗹𝘁𝗵 𝗔𝘀𝘀𝗲𝗺𝗯𝗹𝘆 𝗘𝗻𝗱𝗼𝗿𝘀𝗲𝘀 𝗟𝗮𝗻𝗱𝗺𝗮𝗿𝗸 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲 𝗥𝗲𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻 🌍🔬🎉】   The 𝟳𝟵𝘁𝗵 𝗪𝗼𝗿𝗹𝗱 𝗛𝗲𝗮𝗹𝘁𝗵 𝗔𝘀𝘀𝗲𝗺𝗯𝗹𝘆 ({hashtag|\#|WHA}) has officially adopted the resolution, “Precision medicine: a path towards targeted, personalized, and equitable care” — a pivotal moment for global health innovation.   We are honoured that our Chief Executive Officer, Dr Hon-Yin Brian Chung, contributed a testimonial presented at the WHA alongside representatives from around the world:   "The resolution advances precision medicine as the critical next step — evolving its success with rare diseases to transform care for common conditions and integrate tailored approaches into healthcare systems worldwide. Driven by multi-omics data, AI, and global collaboration, this shift shortens diagnostic journeys and enables personalised treatment. To improve health outcomes for all populations, the resolution calls for broadening representation in research and health data, while building region-specific tools and resources—making equity a core pillar of implementation."   Through this resolution, Member States of World Health Organization commit to a comprehensive approach that includes developing national policies and infrastructure for precision medicine, strengthening workforce capacity and governance frameworks, and ensuring safe, ethical and equitable integration of precision medicine into health systems while prioritising equity and inclusion in scientific advances.   This milestone directly reinforces HKGI’s mission to accelerate the advancement of genomic medicine in Hong Kong, enhancing community well-being and contributing to the city’s development as an international health and medical innovation hub. We look forward to contributing to this global momentum towards equitable precision medicine for all! 🌟   📖 Learn more: https://lnkd.in/gR\_6zucy   {hashtag|\#|HKGI} {hashtag|\#|HongKongGenomeInstitute} {hashtag|\#|PrecisionMedicine} {hashtag|\#|Genomics} {hashtag|\#|WorldHealthOrganization} {hashtag|\#|WHA79} {hashtag|\#|GlobalHealth} {hashtag|\#|PublicHealth} {hashtag|\#|HealthEquity} {hashtag|\#|AI}

testing {hashtag|\#|HKGI} {hashtag|\#|HKGP} {hashtag|\#|HongKongGenomeInstitute} {hashtag|\#|GenomicMedicine} {hashtag|\#|GenomeProject} {hashtag|\#|GenomeDatabase}

test

【International Genomic Medicine Symposium - Panel 4】   Building on the momentum of the Symposium, Panel 4 explored how innovative access pathways and artificial intelligence (AI) are advancing rare disease care. Prof Gareth Baynam and Prof Yong Chen shared insightful perspectives on turning these innovations into real‑world impact for patients. 🌍✨   💬 Session Chairperson: Prof Lau Chak‑sing, BBS, JP Vice‑President & Pro‑Vice‑Chancellor (Health) HKUMed – The University of Hong Kong Board Member, Hong Kong Genome Institute Hong Kong, China   📌 Topic 1: UTOPIA: Unlocking Treatment Options, Personalised In‑Time Access  🗣️ Prof Gareth Baynam Medical Director Rare Care Centre, Perth Children’s Hospital Australia   📌 Topic 2: Modernizing Rare Diseases Studies with AI  🗣️ Prof Yong Chen Professor of Biostatistics, University of Pennsylvania USA   🎥 Watch the full session: https://lnkd.in/gjmt5TFt   {hashtag|\#|HKGI} {hashtag|\#|GenomicMedicine} {hashtag|\#|HKGP} {hashtag|\#|InternationalGenomicMedicineSymposium} {hashtag|\#|PrecisionMedicine} {hashtag|\#|ArtificialIntelligence} {hashtag|\#|GlobalHealth}

【𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝗥𝗮𝗿𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗖𝗮𝗿𝗲 𝘁𝗵𝗿𝗼𝘂𝗴𝗵 𝗚𝗲𝗻𝗼𝗺𝗶𝗰 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻】   Rare diseases may affect small patient populations individually, but collectively they affect over 300 million people worldwide. To bridge the gap between scientific discovery and clinical care, we must move beyond individual breakthroughs towards a coordinated, technology-driven journey of care. 🏞️⚕️   We were honoured to participate in the 𝗔𝘀𝗶𝗮 𝗦𝘂𝗺𝗺𝗶𝘁 𝗼𝗻 𝗚𝗹𝗼𝗯𝗮𝗹 𝗛𝗲𝗮𝗹𝘁𝗵 ({hashtag|\#|𝗔𝗦𝗚𝗛}), where our Chief Executive Officer, Dr Hon-Yin Brian Chung, chaired a pivotal session: “From Detection to Cure: Accelerating Innovations for Rare Diseases”. The discussion explored how genomic diagnostics, cell and gene therapies, and AI are redefining the patient experience. 🤖   “The key priorities are early patient involvement, multi-sector collaboration, and the thoughtful use of technology – not falling into the pitfall of solutions that don’t truly serve the diseases we aim to treat,” shared Dr Chung.    At HKGI, we remain dedicated to expanding the reach of genomic medicine, shortening the diagnostic odyssey, and ensuring that innovation translates into tangible outcomes for patients and their families. 💙   Our sincere thanks to the {hashtag|\#|𝗛𝗞𝗧𝗗𝗖} and fellow speakers for their visionary insights: Dr Francesco Cutrale, Dr Inna MENKOVA, Ms Rute Fernandes, Prof Leszek Lisowski, PhD, MBA, and Dr Zicai Liang.   {hashtag|\#|HKGI} {hashtag|\#|HKGP} {hashtag|\#|HongKongGenomeInstitute} {hashtag|\#|GenomicMedicine} {hashtag|\#|ASGH2026} {hashtag|\#|RareDiseases} {hashtag|\#|Innovation} {hashtag|\#|PrecisionMedicine} {hashtag|\#|HealthTech} {hashtag|\#|HKTDC} {hashtag|\#|AsiaSummitOnGlobalHealth}

【International Genomic Medicine Symposium - Panel 3】   How do we bridge the gap between a laboratory discovery and global clinical practice? ✍️🧬   Panel 3 of our Symposium turned the spotlight on the critical role of medical publishing. The session explored the challenges and opportunities in research dissemination, with Dr Chloe Wilson, Senior Medical Editor at The Lancet, sharing insights on communicating scientific findings effectively to a global audience.    💬 Session Chairperson Prof Philip Chiu, JP CUHK Medicine Hong Kong, China   📌 Topic: Medical Publishing: Challenges and Opportunities  🗣️Speaker:  Dr Chloe Wilson Senior Medical Editor, The Lancet Group   🎥 Watch the full session: https://lnkd.in/gGTb3cFb   {hashtag|\#|HKGI} {hashtag|\#|GenomicMedicine} {hashtag|\#|HKGP} {hashtag|\#|InternationalGenomicMedicineSymposium} {hashtag|\#|PrecisionMedicine} {hashtag|\#|MedicalPublishing} {hashtag|\#|ScientificCommunication}